Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06391645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06391645 · ClinicalTrials.gov record · last posted 2024-04-30

Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis

Name: Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis — clinical trial record (NCT06391645)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NATURAL

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorBeijing Tiantan Hospital

Started2024-05

View on ClinicalTrials.gov ↗

Record status

This record was last updated April 30, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases, with most patients dying from respiratory failure 3-5 years after the onset. The purpose of this study is to explore the efficacy and safety of nerve growth factor (NGF) encapsulated with 2-methacryloyloxyethyl phosphorylcholine (MPC) nanocapsules in the treatment of ALS patients.

Trial Details

NCT Number	NCT06391645
Lead Sponsor	Beijing Tiantan Hospital Collaborators: Beijing University of Chemical Technology, Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation
Conditions	Amyotrophic Lateral Sclerosis
Enrollment	60 participants
Start Date	2024-05
Primary Completion	2025-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2024-04-30